Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ketoconazole Clear all
Completed Phase 1 Interventional

A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS

NCT00000992
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Itraconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Abiraterone Post Ketoconazole for Prostate Cancer

NCT01199146
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 3 Interventional

Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

NCT00000579
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Lung Diseases
Interventions
Low Tidal Volume Ventilation, Positive End-Expiratory Pressure, Lysofylline, Methylprednisolone, Ketoconazole, Fluid Management, Pulmonary Artery Catheter
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
20
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

NCT00503451
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Neoplasms
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 17, 2026, 1:03 AM EDT
Terminated Phase 1Phase 2 Interventional

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

NCT01535157
View directory record Official record
Conditions
Ovarian Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasms, Primary Peritoneal Carcinoma
Interventions
Fenretinide/LXS + Ketoconazole
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

NCT01454076
View directory record Official record
Conditions
Nonhematologic Malignancies, Lymphoma
Interventions
Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

NCT00659555
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, Ketoconozole tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors

NCT00096317
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone, ketoconazole
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

NCT00419783
View directory record Official record
Conditions
Healthy
Interventions
Bilastine, Bilastine & Ketoconazole, Moxifloxacin, Placebo
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 2 Interventional

Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy

NCT00309894
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim, ketoconazole, therapeutic hydrocortisone
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 120 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 17, 2026, 1:03 AM EDT
Terminated Phase 1 Interventional

Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma

NCT02163356
View directory record Official record
Conditions
Recurrent Neuroblastoma, Neuroblastoma
Interventions
Fenretinide/LXS Oral Powder, Ketoconazole, Vincristine
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
Up to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Chicago, Illinois • Dallas, Texas • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers

NCT01149785
View directory record Official record
Conditions
Healthy
Interventions
crizotinib, ketoconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers

NCT02198170
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ketoconazole-placebo, placebo-ketoconazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2015 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

NCT01340846
View directory record Official record
Conditions
Cancer
Interventions
Warfarin, Ketoconazole, Gemfibrozil, GSK2118436 150mg, GSK2118436 75mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Scottsdale, Arizona • Sarasota, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Ketoconazole Cream 2%

NCT04203342
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA), Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
Drug
Lead sponsor
Douglas Pharmaceuticals America Ltd
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Brandon, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

NCT00403559
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Elidel, Ketoconazole Cream
Drug
Lead sponsor
Dermatology Specialists Research
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo

NCT01203189
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
ketoconazole 2% foam, ketoconazole 2% shampoo
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus

NCT00302224
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
2S, 4R Ketoconazole (DIO-902)
Drug
Lead sponsor
DiObex
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Omaha, Nebraska • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2008 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 4 Interventional Results available

Effect of Ketoconazole on Breathlessness

NCT01378520
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
ketoconazole, inert powder
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 17, 2026, 1:03 AM EDT
Terminated Phase 3 Interventional Results available

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

NCT00024167
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium, Ketoconazole, Prednisone, Vinblastine, Strontium chloride Sr 89, Dexamethasone
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
40
States / cities
Gainesville, Georgia • Savannah, Georgia • Hines, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Study of Rapamycin Plus Ketoconazole in Advanced Cancers

NCT00708591
View directory record Official record
Conditions
Advanced Cancer
Interventions
Rapamycin, Ketoconazole
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.

NCT00388596
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2008 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers

NCT01124760
View directory record Official record
Conditions
Pharmacokinetics
Interventions
AZD9742, Diltiazem, ketoconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 17, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

NCT01026415
View directory record Official record
Conditions
Carcinomas, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Neoplasms
Interventions
brentuximab vedotin, rifampin, midazolam, ketoconazole
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Duarte, California • Denver, Colorado • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 17, 2026, 1:03 AM EDT